You may have seen the recent news that advances in cellular engineering have now made it possible to target CAR T-cell therapy against solid tumors. This got us wondering – if CAR T-cell therapy, which is potentially curative in the liquid tumor space, proves effective in solid tumors as well, what does this mean for the targeted therapies and immuno-oncology agents which are currently dominating the treatment landscape in solid tumors?